Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Sinovac Biotech Ltd's Business Segments
Sinovac Biotech Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
Member
Total Revenue
$ 386
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member93.6%
- CN76.9%
- Vaccines Sales2.8%
- Vaccine Pharmacovigilance Services0.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 361 | 93.6% |
| CN | $ 297 | 76.9% |
| Vaccines Sales | $ 11 | 2.8% |
1 more segments available
Sign in to unlock the full Sinovac Biotech Ltd dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Member93.6%
- CN76.9%
- Vaccines Sales2.8%
- Vaccine Pharmacovigilance Services0.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 361 | 93.6% |
| CN | $ 297 | 76.9% |
| Vaccines Sales | $ 11 | 2.8% |
1 more segments available
Sign in to unlock the full Sinovac Biotech Ltd dataset.
Revenue Share by Country - FY
- CN82.3%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| CN | $ 297 | 82.3% |
Description of Sinovac Biotech Ltd
Sinovac Biotech Ltd is a biopharmaceutical company headquartered in Beijing, China. It was established in 1999 and specializes in research, development, manufacturing and commercialization of vaccines for various infectious diseases.
Sinovac has a strong pipeline of vaccines, which cover a broad range of diseases such as hepatitis A, hepatitis B, influenza, human rabies, human papillomavirus (HPV), Japanese encephalitis, enterovirus 71, and SARS-CoV-2. The company’s experience in vaccine development has allowed it to be recognized globally as a pioneer in the field of vaccine R&D.
One of Sinovac’s most significant achievements is the development of the inactivated vaccine against COVID-19, CoronaVac. CoronaVac has been approved for emergency distribution in many countries, including Brazil, Chile, Indonesia, and Turkey. The vaccine has undergone three phases of clinical trials, showing an efficacy rate of 91.25% after two doses in phase III trials in Turkey, and has been distributed globally through a network of partners and agents.
Apart from COVID-19, Sinovac’s other key products include Healive, an inactivated hepatitis A vaccine; Anflu, a split-virion influenza vaccine; Panflu, a pandemic H1N1 influenza vaccine; and Ev71 vaccine, a vaccine against hand, foot, and mouth disease.
Sinovac has four production facilities; three in China, and one in Brazil. The company’s state-of-the-art manufacturing facilities have the capacity to produce more than 300 million doses of vaccines annually. The company has partnerships with many pharmaceutical companies in China, Europe, Latin America, and other regions, which help distribute its products globally.
Apart from vaccine development, Sinovac is committed to providing affordable and accessible vaccines to people. The company has collaborated with many local organizations to set up vaccination programs, especially in underdeveloped countries.
In conclusion, Sinovac Biotech is a highly respected and prominent biopharmaceutical company that is focused on providing innovative vaccines to the world’s population. The company is at the forefront of vaccine development and has played a significant role in fighting pandemics such as COVID-19, hepatitis A, and influenza. Its dedication to producing safe and effective vaccines at an affordable price has made it a leading player in the global vaccine industry.
Sinovac has a strong pipeline of vaccines, which cover a broad range of diseases such as hepatitis A, hepatitis B, influenza, human rabies, human papillomavirus (HPV), Japanese encephalitis, enterovirus 71, and SARS-CoV-2. The company’s experience in vaccine development has allowed it to be recognized globally as a pioneer in the field of vaccine R&D.
One of Sinovac’s most significant achievements is the development of the inactivated vaccine against COVID-19, CoronaVac. CoronaVac has been approved for emergency distribution in many countries, including Brazil, Chile, Indonesia, and Turkey. The vaccine has undergone three phases of clinical trials, showing an efficacy rate of 91.25% after two doses in phase III trials in Turkey, and has been distributed globally through a network of partners and agents.
Apart from COVID-19, Sinovac’s other key products include Healive, an inactivated hepatitis A vaccine; Anflu, a split-virion influenza vaccine; Panflu, a pandemic H1N1 influenza vaccine; and Ev71 vaccine, a vaccine against hand, foot, and mouth disease.
Sinovac has four production facilities; three in China, and one in Brazil. The company’s state-of-the-art manufacturing facilities have the capacity to produce more than 300 million doses of vaccines annually. The company has partnerships with many pharmaceutical companies in China, Europe, Latin America, and other regions, which help distribute its products globally.
Apart from vaccine development, Sinovac is committed to providing affordable and accessible vaccines to people. The company has collaborated with many local organizations to set up vaccination programs, especially in underdeveloped countries.
In conclusion, Sinovac Biotech is a highly respected and prominent biopharmaceutical company that is focused on providing innovative vaccines to the world’s population. The company is at the forefront of vaccine development and has played a significant role in fighting pandemics such as COVID-19, hepatitis A, and influenza. Its dedication to producing safe and effective vaccines at an affordable price has made it a leading player in the global vaccine industry.
Segments of Sinovac Biotech Ltd:
Sinovac Biotech Ltd operates within the biopharmaceutical industry with a strategic focus on the development, manufacturing, and commercialization of vaccines targeted at infectious diseases. The company primarily segments its operations into two main categories:
1. Human Health Vaccines:
- This segment encompasses the research, development, manufacturing, and sale of vaccines aimed at preventing and treating infectious diseases that affect human populations. Sinovac’s human health vaccine portfolio includes:
- Hepatitis Vaccines: This includes vaccines specifically developed for the prevention of Hepatitis A and Hepatitis B, both of which are significant public health concerns globally.
- Human Papillomavirus (HPV) Vaccine: A vaccine designed to prevent cancers caused by HPV.
- Seasonal Influenza Vaccine (Anflu): A trivalent seasonal influenza vaccine designed to combat the typical strains of influenza that circulate in a given year.
- COVID-19 Vaccine (CoronaVac): A relatively recent addition to their portfolio, developed during the global COVID-19 pandemic to provide immunity against the SARS-CoV-2 virus.
2. Animal Health Vaccines:
- The animal health segment is focused on the development and production of vaccines intended for livestock, poultry, and pets. These vaccines play a crucial role in the prevention and treatment of infectious diseases that can impact animal health and, subsequently, human populations through zoonotic transmissions. This includes vaccines for:
- Livestock diseases (such as swine fever).
- Poultry diseases.
- Companion animal diseases.
Products Offered by Sinovac Biotech Ltd:
Sinovac Biotech boasts an array of vaccines for both human and animal health. Some of their flagship products include:
1. CoronaVac:
- This is Sinovacs inactivated virus COVID-19 vaccine, which has undergone extensive clinical trials showing varying efficacy rates. It has been authorized for emergency use in numerous countries, making it a pivotal part of global vaccination efforts against COVID-19.
2. Healive:
- A vaccine targeted at Hepatitis A, offered in two dosages to cater to different immunization schedules. It has received regulatory approval in more than ten countries, demonstrating its broad acceptance and reliability.
3. Anflu:
- This trivalent seasonal influenza vaccine is formulated to target the most common influenza virus strains each season. It is robustly approved within China and is part of national immunization programs.
4. Enterovirus 71 (EV71) Vaccine:
- A specialized vaccine designed to prevent Hand, Foot, and Mouth Disease (HFMD), particularly outbreaks triggered by EV71 strains. This vaccine is significant in regions where such outbreaks are prevalent.
5. Animal Vaccines:
- Sinovac also produces a range of vaccines for various animal species to enhance animal health and prevent disease spread across animal populations.
Services Offered by Sinovac Biotech Ltd:
In addition to its vaccine products, Sinovac Biotech provides a suite of complementary services associated with vaccine development and distribution:
1. Manufacturing and Supply:
- Sinovac is engaged in manufacturing its vaccines in compliance with international quality standards to ensure that products are available to meet global health demands.
2. Clinical Trials:
- The company invests in rigorous clinical trials to assess the safety and efficacy of its vaccine candidates prior to market approval. This process is critical to ensuring that all products meet the necessary regulatory requirements.
3. Research and Development (R&D):
- Ongoing investment in R&D is a cornerstone of Sinovac’s strategy, enabling the company to innovate and expand its portfolio to include new vaccines that address emerging infectious diseases.
4. Marketing and Distribution:
- Sinovac employs a strategic marketing and distribution network to ensure its vaccine products reach in a timely manner the markets where they are needed. This includes partnerships with governmental and non-governmental organizations, pharmaceutical companies, and healthcare institutions worldwide to facilitate access.
Through these segments, products, and services, Sinovac Biotech Ltd positions itself as a key player in the global fight against infectious diseases, making significant contributions to both human and animal health.
Sinovac Biotech Ltd operates within the biopharmaceutical industry with a strategic focus on the development, manufacturing, and commercialization of vaccines targeted at infectious diseases. The company primarily segments its operations into two main categories:
1. Human Health Vaccines:
- This segment encompasses the research, development, manufacturing, and sale of vaccines aimed at preventing and treating infectious diseases that affect human populations. Sinovac’s human health vaccine portfolio includes:
- Hepatitis Vaccines: This includes vaccines specifically developed for the prevention of Hepatitis A and Hepatitis B, both of which are significant public health concerns globally.
- Human Papillomavirus (HPV) Vaccine: A vaccine designed to prevent cancers caused by HPV.
- Seasonal Influenza Vaccine (Anflu): A trivalent seasonal influenza vaccine designed to combat the typical strains of influenza that circulate in a given year.
- COVID-19 Vaccine (CoronaVac): A relatively recent addition to their portfolio, developed during the global COVID-19 pandemic to provide immunity against the SARS-CoV-2 virus.
2. Animal Health Vaccines:
- The animal health segment is focused on the development and production of vaccines intended for livestock, poultry, and pets. These vaccines play a crucial role in the prevention and treatment of infectious diseases that can impact animal health and, subsequently, human populations through zoonotic transmissions. This includes vaccines for:
- Livestock diseases (such as swine fever).
- Poultry diseases.
- Companion animal diseases.
Products Offered by Sinovac Biotech Ltd:
Sinovac Biotech boasts an array of vaccines for both human and animal health. Some of their flagship products include:
1. CoronaVac:
- This is Sinovacs inactivated virus COVID-19 vaccine, which has undergone extensive clinical trials showing varying efficacy rates. It has been authorized for emergency use in numerous countries, making it a pivotal part of global vaccination efforts against COVID-19.
2. Healive:
- A vaccine targeted at Hepatitis A, offered in two dosages to cater to different immunization schedules. It has received regulatory approval in more than ten countries, demonstrating its broad acceptance and reliability.
3. Anflu:
- This trivalent seasonal influenza vaccine is formulated to target the most common influenza virus strains each season. It is robustly approved within China and is part of national immunization programs.
4. Enterovirus 71 (EV71) Vaccine:
- A specialized vaccine designed to prevent Hand, Foot, and Mouth Disease (HFMD), particularly outbreaks triggered by EV71 strains. This vaccine is significant in regions where such outbreaks are prevalent.
5. Animal Vaccines:
- Sinovac also produces a range of vaccines for various animal species to enhance animal health and prevent disease spread across animal populations.
Services Offered by Sinovac Biotech Ltd:
In addition to its vaccine products, Sinovac Biotech provides a suite of complementary services associated with vaccine development and distribution:
1. Manufacturing and Supply:
- Sinovac is engaged in manufacturing its vaccines in compliance with international quality standards to ensure that products are available to meet global health demands.
2. Clinical Trials:
- The company invests in rigorous clinical trials to assess the safety and efficacy of its vaccine candidates prior to market approval. This process is critical to ensuring that all products meet the necessary regulatory requirements.
3. Research and Development (R&D):
- Ongoing investment in R&D is a cornerstone of Sinovac’s strategy, enabling the company to innovate and expand its portfolio to include new vaccines that address emerging infectious diseases.
4. Marketing and Distribution:
- Sinovac employs a strategic marketing and distribution network to ensure its vaccine products reach in a timely manner the markets where they are needed. This includes partnerships with governmental and non-governmental organizations, pharmaceutical companies, and healthcare institutions worldwide to facilitate access.
Through these segments, products, and services, Sinovac Biotech Ltd positions itself as a key player in the global fight against infectious diseases, making significant contributions to both human and animal health.